Good post, mfm, my feelings exactly! I was surprised at the volume of the sell off and how rapidly it went down. It makes me wonder if it was coordinated? I'm not that familiar with groups like Money Runner. I understand longs were disappointed that more data wasn't presented, but the sell off seemed disproportionate. I'm not selling. I suspect in the coming days and weeks the pps will come back and we'll resume our progress.
Gerald has many catalysts waiting in the wings. Maybe next week once all the blood letting is done it will be a good time to release Retinitis Functionality data or Wolframs data? Or perhaps Gerald will soon announce Revenue Guidance. Sell down here if you want, but I think you'll regret it big time. This will not stay down here for long.
Or, he wants the weak hands to leave so the pps can find a bottom. It would have been useless for him to speak reason to shareholders today that were consumed with irrationality and fear! Plus, he needs to rest and write the blog Monday morning after he's able to gather himself from the busy Conference and travel to New York.
slurppy: I am actually moving today. (Homes) So I will be signing off for awhile. Gerald has not communicated the LymPro testing process very well. But Beckton Dickenson is for real. They have verified the underlying science and would not have allowed their name to be on the posters in Copenhagen if they had any doubts. Yesterday's data was an incomplete portion of the "bridge study." A much larger study (150 to 200 patient) will be performed once we are in our CLIA partner's lab to validate the blood test. By the time we commercialize in November we will have the sens & spec numbers in the mid 90s. The old version 1 data that was presented in Copenhagen from 2002 and 2012 had 90 and 95 percent numbers. We'll do better than that. Top notch diagnostic experts have come to AMBS to help launch LymPro. They know they have a winner. The communication has been botched in my opinion. But that can be fixed. LymPro doesn't need to be fixed, it is great! That's why this sell of is so tragic for the weak hands. They don't ;understand and are panic selling into the hands of those paying the bashers! Isn't America great? Signing out.
None of the science about LymPro has changed. They switched from version 1 to version 2 and didn't have the complete data to report on yesterday. The reason they switched to version 2 is because it is significantly better than version 1, which has yielded sens & spec numbers above 90. Traders jumped on the incomplete numbers and caused panic. That is why the stock dropped 40%. I'm warning longs who are wavering: you will regret selling now. This stock will rebound. Lincoln Park Capital has purchased tens of millions of shares above .11 cents. They are going to drive up this stock back to where it was... and beyond... as soon as the panic selling subsides! Don't believe these bashers out today in droves. Why would they be out there in force except to cause you to give up your shares? If they were sincere shareholders they wouldn't be bashing because that would cause their own shares to go down in value. They only want you to sell your shares at a loss as a result of their complaining. But do what you have to do. I'm telling you though, LymPro is fine! MANF is fine. The reasons you bought this stock and rode it up are still valid. You'll regret letting this short term crisis separate you from your shares.
wiki: Nothing has changed. You're a rookie at Biotech investing and if you choose to sell now you will lose out. Your ignorance is overwhelming! I will post whenever I feel like it. And I feel like it today!
If it's a LymPro cake....I'll take it and eat it, gladly! I cannot believe how many rookie shareholders will get screwed by the bashers and sell out prematurely! This pps will be back to the .15 to .18 cent range in a week.
Robert, I agree. Gerald could communicate better with lay investors. I am still a firm believer in LymPro and MANF. I am still a firm believer in Gerald and his team. One day Gerald will learn how to avoid these gaffes in communication.
gone for ever: Then be gone...forever. If you didn't know Biotech stocks are highly volatile, you shouldn't be here. We were trading at .11 cents where we are now a couple of months ago. We will bounce back soon. The weak hands won't survive. They never do in these types of stocks. That's just the way it is. Sorry my insight has become illusive to you now that the stock fell sharply yesterday. But I'm not the one that has changed.
AMBS tends to communicate more to scientists than investors. That is a part of what is going on here. John Commissiong, Gerald's Dad, is a pretty big scientist. He discovered MANF after all. I think the sell off was way over done, mainly because most of us investors don't really understand the underlying science of what was communicated yesterday. We were all wanting big fat and juicy spec & sens numbers in the mid 90s we could wrap our arms around. Well, the science community doesn't always accommodate our lack of understanding. Gerald is moving LymPro toward commercialization in a way that will impress the KOLs (Key Opinion Leaders) in the AD industry. He is doing that and making great progress. By the time we commercialize LymPro in November and Gerald is doing his media blitz, he'll have it dumbed down so non-science people can grasp it. He'll have with LymPro version 2 his mid 90s numbers so we can all be elated by our brilliant Biotech investment when the pps goes through the roof making us millionaires! That will all still happen, but we have to grow up first. This has been amazing to see a big bunch of weenies lose their nerve!! LOL. The Smart Money will be rewarded.
This has been a massive emotional sell off. Because we went up to .193 cents in rather dramatic fashion, people were fearful the pps would fall...and it did. But once the dust settles cooler heads will reconstruct why the pps shot up to .193 cents in the first place and they will realize everything scientifically sound about the company is still there!! We will be stronger as a result of losing the less committed. My analysis doesn't ignore the fact that Gerald mishandled the communication of things...which he frequently does. But I'm not calling for his removal, on the contrary, he is doing a great job. Biotech stocks are volatile. We will have more violent swings in the future. But we still have LymPro and MANF, and I'm going to still be here. Good luck with your emotions everyone.
You know, Professor, his mistake with Creatable & Credible reveals what goes on deep with our brain. Phonetics and spelling combine in magical ways. My wife does this all the time. I've actually started documenting the "pairs" of words she comes up with like these. It's fascinating! I'm into the etymology of words.
rokony: I know what you mean. But, Beckton Dickenson has validated LymPro and they have those past tests with higher than 90% spec & sens numbers. Gerald has the "Pilot Test" done in Q1 2014 plus the small number tested in the "Bridge Test" that he'll give a summary of today. I think Gerald is confident that version 1 of Lympro was good, but version 2 is off the charts. 95% is a lot better than 90%. So what may seem like game playing, as if he didn't really have the goods, is really strategic positioning. I think the data will be great. We'll get some today, and more soon. But I think our new ally, Michael Moffat (Cavendish) is being positioned today after Dr. Arendt and Dr. Kirby for a reason! I'm hoping for a big surprise, more than what the data alone would give us!!
My gut is telling me that Gerald is confident in the version 2 data and he doesn't really care that there aren't very many patients having been tested so far. I think there is a surprise coming from CAVENDISH that will trump data.